$PBIO Pressure BioSciences Shatters Preconceived Nanoemulsion Stability, Performance, and Production Limits: Produces CBD Oil Nanoemulsions with 18 Month Stability
https://www.accesswire.com/679117/pressure-bi...-stability
UST Platform's Ultra-low Droplet Sizes and Test Verified Stability Portends Revolution in Major Markets
SOUTH EASTON, MA / ACCESSWIRE / December 22, 2021 / Pressure BioSciences, Inc. (OTCQB
BIO) ("PBI" or the "Company"
, a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and innovative services to the worldwide biotechnology, biotherapeutics, cosmetics, nutraceuticals, agrochemical, and food & beverage industries, today announced that hemp-derived cannabidiol ("CBD" processed with its patented Ultra Shear Technology™ ("UST™" platform produced high-quality water-soluble nanoemulsions of CBD oil in water that have now demonstrated rock-solid visual and analytical stability 18 months after production and baseline testing.
CBD is a widely popular therapeutic for relief of anxiety, depression, and PTSD, as well as chronic inflammatory and neuropathic pain. It is FDA-approved for use in the control of epileptic seizures in Lennox-Gastaut syndrome and Dravet syndrome. Early research suggests that CBD reduces spasticity in multiple sclerosis and may lessen the severity of neurological symptoms associated with Alzheimer's Disease, Parkinson's disease, and schizophrenia. CBD is under investigation as a palliative adjunctive therapy in cancer.
However, CBD is insoluble in water and is poorly absorbed by the human body. The World Health Organization (WHO) estimates that as little as 6% of CBD is absorbed via current oral delivery routes. Thus, most ingested CBD is wasted, passing through the body without being absorbed. Consequently, there is enormous interest in the development of truly water-soluble CBD to deliver efficient dosing, absorption, bioavailability, and benefit from CBD products (e.g., foods and beverages, therapeutics).
Dr. Alexander V. Lazarev, Chief Science Officer of PBI, explained: "Nanoemulsions, liposomes, and solid lipid nanoparticles present many exciting opportunities as pharmaceutical and nutraceutical delivery systems. The smaller the size of oil droplets or particles the better the stability and bioavailability of these preparations. Once the droplets/particles reach below about 100 nanometers, nanoemulsions appear optically clear and remain stable for months or even years, thus maintaining their aesthetic appeal, bioavailability, and importantly, their shelf life. Moreover, these preparations can be filter-sterilized to comply with FDA requirements for injectable drugs. Today we are pleased to announce that our enabling, affordable, and scalable UST process has been shown to create nanoemulsions that maintain rock-solid stability, excellent water solubility, and pristine visual clarity at room temperature for at least 18 months. These results offer the potential to significantly increase shelf-life and effectiveness for CBD and a multitude of other oil-based products in use today."
Mr. Gary B. Smejkal, Senior Research Scientist at PBI, explained the Company's breakthrough: "The intense fluid shearing in UST progressively decreases oil droplet size with each cycle, making the method highly tunable while enabling the user to select and reliably reach a target droplet size. We have demonstrated that our platform consistently produces CBD nanoemulsions of uniform 30-40 nm droplet sizes that are stable at room temperature for at least 18 months. Measurements of droplet size by Dynamic Light Scattering (DLS) over time courses at various temperatures have shown that particle size remains unchanged over prolonged storage at room temperature or refrigeration, a major indication of nanoemulsion stability. Clarity, quantified by UV/Vis spectroscopy, also remains unchanged for equally long periods of time, making the CBD nanoemulsion visually undetectable when infused into bottled water or other beverages."
https://www.accesswire.com/679117/pressure-bi...-stability
UST Platform's Ultra-low Droplet Sizes and Test Verified Stability Portends Revolution in Major Markets
SOUTH EASTON, MA / ACCESSWIRE / December 22, 2021 / Pressure BioSciences, Inc. (OTCQB
BIO) ("PBI" or the "Company" , a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and innovative services to the worldwide biotechnology, biotherapeutics, cosmetics, nutraceuticals, agrochemical, and food & beverage industries, today announced that hemp-derived cannabidiol ("CBD" processed with its patented Ultra Shear Technology™ ("UST™" platform produced high-quality water-soluble nanoemulsions of CBD oil in water that have now demonstrated rock-solid visual and analytical stability 18 months after production and baseline testing. CBD is a widely popular therapeutic for relief of anxiety, depression, and PTSD, as well as chronic inflammatory and neuropathic pain. It is FDA-approved for use in the control of epileptic seizures in Lennox-Gastaut syndrome and Dravet syndrome. Early research suggests that CBD reduces spasticity in multiple sclerosis and may lessen the severity of neurological symptoms associated with Alzheimer's Disease, Parkinson's disease, and schizophrenia. CBD is under investigation as a palliative adjunctive therapy in cancer.
However, CBD is insoluble in water and is poorly absorbed by the human body. The World Health Organization (WHO) estimates that as little as 6% of CBD is absorbed via current oral delivery routes. Thus, most ingested CBD is wasted, passing through the body without being absorbed. Consequently, there is enormous interest in the development of truly water-soluble CBD to deliver efficient dosing, absorption, bioavailability, and benefit from CBD products (e.g., foods and beverages, therapeutics).
Dr. Alexander V. Lazarev, Chief Science Officer of PBI, explained: "Nanoemulsions, liposomes, and solid lipid nanoparticles present many exciting opportunities as pharmaceutical and nutraceutical delivery systems. The smaller the size of oil droplets or particles the better the stability and bioavailability of these preparations. Once the droplets/particles reach below about 100 nanometers, nanoemulsions appear optically clear and remain stable for months or even years, thus maintaining their aesthetic appeal, bioavailability, and importantly, their shelf life. Moreover, these preparations can be filter-sterilized to comply with FDA requirements for injectable drugs. Today we are pleased to announce that our enabling, affordable, and scalable UST process has been shown to create nanoemulsions that maintain rock-solid stability, excellent water solubility, and pristine visual clarity at room temperature for at least 18 months. These results offer the potential to significantly increase shelf-life and effectiveness for CBD and a multitude of other oil-based products in use today."
Mr. Gary B. Smejkal, Senior Research Scientist at PBI, explained the Company's breakthrough: "The intense fluid shearing in UST progressively decreases oil droplet size with each cycle, making the method highly tunable while enabling the user to select and reliably reach a target droplet size. We have demonstrated that our platform consistently produces CBD nanoemulsions of uniform 30-40 nm droplet sizes that are stable at room temperature for at least 18 months. Measurements of droplet size by Dynamic Light Scattering (DLS) over time courses at various temperatures have shown that particle size remains unchanged over prolonged storage at room temperature or refrigeration, a major indication of nanoemulsion stability. Clarity, quantified by UV/Vis spectroscopy, also remains unchanged for equally long periods of time, making the CBD nanoemulsion visually undetectable when infused into bottled water or other beverages."
